Drugs / 18F-FDOPA
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04246437 | Feb 2020 → Feb 2027 expected | Lewy body dementia, Parkinson disease, pure autonomic failure | Daniel Claassen | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07542158 | May 2025 → Jun 2030 expected | glioma, neuroendocrine neoplasm, parkinsonian disorder | Akiva Mintz | Enrolling by invitation | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05512403 | Jun 2023 → Dec 2025 overdue | glioma | Central Hospital, Nancy, France | Recruiting | No outcome recorded |
| Phase 3 | NCT03998852 | Apr 2021 → Apr 2027 expected | — | University Hospital, Bordeaux | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03973502 | Jun 2017 → May 2023 | Parkinson disease, hepatitis B virus infection, hepatitis C virus infection | National Taiwan University Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03581305 Comparator | Nov 2018 → Apr 2022 | AIDS dementia complex, HIV infectious disease, depressive disorder | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]FDOPA | “One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA.” NCT03973502 ↗ |
| Modality | Diagnostic / imaging agent | “High resolution positron emission tomography (PET) of the brain and radioligands targeted against the dopaminergic (18F-FDOPA) system.” NCT03581305 ↗ |
| Route | Intravenous | “injected intravenously with 185 MBq (5mCi) 18F-FDOPA” NCT03973502 ↗ |